2023 NAB Show®: Kalray Unveils ngenea®2, A Major Evolution of Its Open Data Management Platform, and Demonstrates It With AWS and Seagate
Kalray (Euronext Growth Paris : ALKAL), today announced the release of ngenea®2, the new version of its open data management and orchestration platform for data-centric applications. Leveraging Kalray’s Data Processor Unit (DPU) acceleration cards and Kalray’s pixstor™ software-defined storage solution, ngenea®2 addresses the challenges faced by a growing number of companies across all industries to be able to process, store, and manage their data faster, more efficiently, and more securely, wherever the data is located and whatever application they use.
ngenea®2 will be demonstrated at NAB 2023 by pixitmedia, Kalray’s subsidiary specialized in storage and data management solutions for the Media & Entertainment industry, in the Amazon (AWS) Innovation Zone and in the booth of its technology partner Seagate.
NEW ADVANCED FEATURES BOOSTED BY KALRAY DPU TECHNOLOGY
An increasing number of companies face challenges in their abilities to store, access, process, and control their data easily and efficiently when working within domains such as HPC, life science, media, finance, and manufacturing, to name a few. ngenea® offers a unique solution to address these challenges. It automates data management to ensure simple and efficient access to data wherever it is needed, on premises or in the cloud, and allows developers and data analysts to run complex data-intensive workflows in an easy and cost-efficient way.
ngenea®2 introduces advanced features to further address these needs. ngenea®2 consolidates data and infrastructure management into a single point of orchestrated control, enabling developers and data scientists to launch new, globally accessible data-centric workflows in seconds, across multiple on-premises, public and private cloud endpoints simultaneously and securely through each phase of their development. ngenea®2 exposes easy-to-use interfaces (“APIs”) to allow integration of third-party storage and application solutions into the ngenea namespace, providing a unified view of and instant global access to real-time data for developers. Moreover, one major evolution of ngenea®2 is its ability to leverage Kalray’s DPUs. With Kalray’s DPUs, ngenea®2 has been designed to give developers the best performance through in-storage NVMe processing and to offer AI-assisted unprecedented levels of insight into unstructured content assets to facilitate data-centric workflows.
DISPLAYING THE LATEST TECHNOLOGIES AT THE MECCA OF BROADCASTING
NAB, held from April 15-19, 2023 in Las Vegas, is one of the largest gatherings of Media & Entertainment (M&E) professionals in the world, featuring the latest technologies, services, and products in the areas of broadcasting, streaming, production, post-production, content creation, and distribution.
At the show, Kalray, through its subsidiary pixitmedia, will demonstrate multiple use cases to highlight how ngenea®2 manages and orchestrates global M&E workflows in diverse environments that include products and services from various technology partners, including AWS and Seagate, but also Adobe, Autodesk, Avid, Blackmagic, and Projective.
DEMONSTRATING AN END-TO-END CLOUD WORKFLOW AT AWS INNOVATION ZONE
At its kiosk in the Amazon Web Services (AWS) Create Innovation Zone (North Hall N2562H), pixitmedia will display a mixed editorial environment in AWS, mirroring a solution that it has in production with a Media & Entertainment Distribution arm of a major motion picture studio.
The demonstration will showcase how Kalray’s pixstor™ and ngenea®2 bring new levels of coherence and efficiency to media production, while improving security, controlling costs, and boosting collaboration. This solution includes an Amazon Elastic Compute Cloud (EC2) workstation in a pixstor™ cloud, with Projective’s Strawberry providing project containerization of a shared storage environment, enabling Adobe, Avid, and Blackmagic DaVinci Resolve participation in the workflow – all using the same core assets.
DEMONSTRATING AUTOMATED MOVEMENT OF MEDIA WITH SEAGATE AND AUTODESK
Also, technology partner Seagate is hosting pixitmedia to display a joint hyperconverged solution with three high-end workstations running Autodesk Flame, Flame Assist, and Blackmagic DaVinci Resolve. The demonstrated solution provides high-performance finishing suites, leveraging high-speed, native access to media data on pixstor™, boosted by Kalray hardware DPU accelerator cards and with ngenea®2 automating the movement of media between a customer NAS, Avid NEXIS, and Tier0 storage.
ABOUT KALRAY
Kalray is a leading provider of hardware and software technologies and solutions for high-performance, data centric markets, from edge to cloud.
Kalray provides a full range of products to enable smarter, more efficient, and energy-wise data-intensive applications and infrastructures. Its offers include its unique patented DPU (Data Processing Unit) processors and acceleration cards as well as its leading-edge software-defined storage and data management offers. Separated or in combination, Kalray’s high-performance solutions allow its customers to improve the efficiency of data centers or design the best solutions in fast-growing sectors such as AI, Media & Entertainment, Life Science, Scientific Research, Edge Computing, Automotive and others.
Founded in 2008 as a spin-off of the well-known French CEA research lab, with corporate and financial investors such as Alliance Venture (Renault-Nissan-Mitsubishi), NXP Semiconductors or Bpifrance, Kalray is dedicated through technology, expertise, and passion to offer more: more for a smart world, more for the planet, more for customers and developers. www.kalrayinc.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230413005705/en/
Contact information
INVESTOR CONTACTS
E
ric BAISSUS
contactinvestisseurs@kalrayinc.com
Phone: + 33 4 76 18 90 71
ACTUS Finance & Communication
Anne-Pauline PETUREAUX
kalray@actus.fr
Phone: + 33 1 53 67 36 72
PRESS CONTACTS
S
ylvie DAM
communication@kalrayinc.com
Phone: +33 4 76 18 90 71
ACTUS Finance & Communication
Serena BONI
sboni@actus.fr
Phone: +33 4 72 18 04 92
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom